Biomarkers associated with checkpoint inhibitors

G. Manson, J. Norwood, A. Marabelle, H. Kohrt, R. Houot

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    137 Citations (Scopus)

    Résumé

    Checkpoint inhibitors (CPI), namely anti-CTLA4 and anti-PD1/PD-L1 antibodies, demonstrated efficacy across multiple types of cancer. However, only subgroups of patients respond to these therapies. Additionally, CPI can induce severe immune-related adverse events (irAE). Biomarkers that predict efficacy and toxicity may help define the patients who may benefit the most from these costly and potentially toxic therapies. In this study, we review the main biomarkers that have been associated with the efficacy (pharmacodynamics and clinical benefit) and the toxicity (irAE) of CPIs in patients.

    langue originaleAnglais
    Pages (de - à)1199-1206
    Nombre de pages8
    journalAnnals of Oncology
    Volume27
    Numéro de publication7
    Les DOIs
    étatPublié - 1 juil. 2016

    Contient cette citation